This study investigates the additional diagnostic value of these novel CSF biomarker candidates as compared to the well-acknowledged combined analysis of tau and Aβ42 in differentiating the dementias AD, DLB, and PDD. This evidence concerns the gene MAPT and Lewy body dementia.